Drug Trial Radar · NCT06535607
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
257
Planned (sponsor's estimate)
Start
Aug 22, 2024
Primary completion
Nov 30, 2028
Study completion Nov 30, 2028
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
eVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer agents in participants with advanced/metastatic solid tumors.
Conditions
- Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)
- Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)
- Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
- Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
- Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)
Interventions
VolrustomigBiological
IV Infusion
CisplatinDrug
IV Infusion
CarboplatinDrug
IV Infusion
PaclitaxelDrug
IV Infusion
5-FUDrug
IV Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: Through study completion, an average of 4 years
- The number of participants with adverse events/serious adverse eventsTime frame: Through study completion, an average of 4 years
Locations
98 sites in 12 countries. Site status is shown where the registry gives one.
Research Site
Los Angeles, California · Withdrawn
Research Site
Baltimore, Maryland · Recruiting
Research Site
New York, New York · Recruiting
Research Site
Stony Brook, New York · Recruiting
Research Site
Columbus, Ohio · Not yet recruiting
Research Site
Columbus, Ohio · Withdrawn
Research Site
Philadelphia, Pennsylvania · Not yet recruiting
Research Site
Clayton, Australia · Recruiting
Research Site
Nedlands, Australia · Recruiting
Research Site
Ijuí, Brazil · Recruiting
Research Site
Londrina, Brazil · Recruiting
Research Site
Natal, Brazil · Recruiting
Research Site
Porto Alegre, Brazil · Not yet recruiting
Research Site
Santo André, Brazil · Not yet recruiting
Research Site
São Caetano do Sul, Brazil · Recruiting
Research Site
Vitória, Brazil · Recruiting
Research Site
Vitória, Brazil · Not yet recruiting
Research Site
Edmonton, Alberta, Canada · Recruiting
Research Site
Montreal, Quebec, Canada · Recruiting
Research Site
Anyang, China · Not yet recruiting
Research Site
Beijing, China · Not yet recruiting
Research Site
Beijing, China · Recruiting
Research Site
Beijing, China · Active not recruiting
Research Site
Beijing, China · Recruiting
Research Site
Beijing, China · Active not recruiting
Research Site
Bengbu, China · Withdrawn
Research Site
Changchun, China · Withdrawn
Research Site
Changchun, China · Recruiting
Research Site
Changsha, China · Completed
Research Site
Changsha, China · Completed
Research Site
Changsha, China · Active not recruiting
Research Site
Changsha, China · Completed
Research Site
Chengdu, China · Completed
Research Site
Chengdu, China · Active not recruiting
Research Site
Chengdu, China · Recruiting
Research Site
Chongqing, China · Active not recruiting
Research Site
Chongqing, China · Withdrawn
Research Site
Dongguan, China · Active not recruiting
Research Site
Dongguan, China · Recruiting
Research Site
Fuzhou, China · Completed
Showing 40 of 98 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.